# Beijing Konruns Pharmaceutical

Source: https://onco.cc/companies/beijing-konruns-pharmaceutical/  
OnCo record `beijing-konruns-pharmaceutical` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Beijing Konruns Pharmaceutical is a Chinese developer in Beijing that sponsors 5 registered cancer trials of KC1036 and S-1.

## Summary

Beijing Konruns Pharmaceutical appears on ClinicalTrials.gov as the industry sponsor of 5 interventional cancer trials (phase 1/2, 2, 3), testing KC1036, S-1, Toripalimab in esophageal squamous cell carcinoma, esophageal squamous cell carcinoma (escc), digestive system tumors, thymic tumors. OnCo records the company from the registry alone: the head office city comes from its registered name, and there are no website, funding or approval claims until they are sourced.

## Fields

- Kind: Company
- Last checked: 2026-09-11
- Also known as: Beijing Konruns Pharmaceutical Co., Ltd.
- Tags: ctgov-sponsor; china; registry-only
- HQ: Beijing, China
- Type: biotech

## Sources

- ClinicalTrials.gov: trials sponsored by Beijing Konruns Pharmaceutical: https://clinicaltrials.gov/search?spons=Beijing%20Konruns%20Pharmaceutical

## Connected records

- trials: [A Study of KC1036 in Adolescents With Advanced Ewing Sarcoma](https://onco.cc/trials/nct06564272/), [A Study of KC1036 in Patients with Advanced Thymic Tumors](https://onco.cc/trials/nct05683886/), [A Study of KC1036 Versus Investigator's Choice of Chemotherapy in Patients With Advanced Esophageal Cancer](https://onco.cc/trials/nct06194734/), [KC1036 in Combination With PD-1 Antibody and Platinum-based Chemotherapy for First-line Advanced Esophageal Cancer](https://onco.cc/trials/nct07481058/)

---
JSON: https://onco.cc/api/v1/entities/beijing-konruns-pharmaceutical.json